Cargando…

Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer

SIMPLE SUMMARY: Endometrial cancer (EC) is diagnosed in almost 400,000 women every year globally and is the sixth most common cancer in women. When diagnosed early, treatment can result in a full recovery; however, when at an advanced stage, fewer than 50% of patients survive beyond 5 years and new...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howard, David, James, David, Murphy, Kate, Garcia-Parra, Jezabel, Pan-Castillo, Belen, Rex, Stuart, Moul, Annemarie, Jones, Eilir, Bilbao-Asensio, Marc, Michue-Seijas, Saul, Lutchman-Singh, Kerryn, Margarit, Lavinia, Francis, Lewis W., Rees, Paul, Gonzalez, Deyarina, Conlan, R. Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962054/ https://www.ncbi.nlm.nih.gov/pubmed/33800911 http://dx.doi.org/10.3390/cancers13051135

Ejemplares similares

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022)

Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer
por: Healey, Gareth D., et al.
Publicado: (2019)

In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer
por: Quintela, Marcos, et al.
Publicado: (2023)

Mechanomimetic 3D Scaffolds as a Humanized In Vitro Model for Ovarian Cancer
por: Paradiso, Francesca, et al.
Publicado: (2022)

Chronic Urinary Infection in Overactive Bladder Syndrome: A Prospective, Blinded Case Control Study
por: Khan, Zainab, et al.
Publicado: (2021)

Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11
por: Younas, Kinza, et al.
Publicado: (2019)

Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells
por: Quintela, Marcos, et al.
Publicado: (2023)

Therapeutic Potential of Microalgae-Derived Bioactive Metabolites Is Influenced by Different Large-Scale Culture Strategies
por: Garcia-Parra, Jezabel, et al.
Publicado: (2022)

Elucidating Novel Targets for Ovarian Cancer Antibody–Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity
por: Onyido, Emenike Kenechi, et al.
Publicado: (2023)

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
por: Buzzetti, Marta, et al.
Publicado: (2021)

Liquid crystal delivery of ciprofloxacin to treat infections of the female reproductive tract
por: Pisano, Simone, et al.
Publicado: (2019)

Pulmonary Delivery of Extracellular Vesicle-Encapsulated Dinaciclib as an Effective Lung Cancer Therapy
por: Yuan, Qian, et al.
Publicado: (2022)

A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia
por: Pariury, Holly, et al.
Publicado: (2023)

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
por: Booher, Robert N., et al.
Publicado: (2014)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

Bcl-x(L) inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas
por: Rello-Varona, Santi, et al.
Publicado: (2019)

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib
por: Ke, Changhong, et al.
Publicado: (2020)

Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
por: Riess, Christin, et al.
Publicado: (2020)

A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer
por: Murphy, Adrian G., et al.
Publicado: (2020)

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
por: Gregory, Gareth P., et al.
Publicado: (2022)

Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9
por: Saqub, Hera, et al.
Publicado: (2020)

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
por: Gojo, Ivana, et al.
Publicado: (2013)

The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
por: Desai, Brijal M., et al.
Publicado: (2013)

Evaluation of CDK9 Inhibition by Dinaciclib in Combination with Apoptosis Modulating izTRAIL for the Treatment of Colorectal Cancer
por: Shen, Xiao, et al.
Publicado: (2023)

iNOS Activation Regulates β-catenin Association with Its Partners in Endothelial Cells
por: Gonzalez, Deyarina, et al.
Publicado: (2012)

Editorial: Exosomes as Therapeutic Systems
por: Corradetti, Bruna, et al.
Publicado: (2021)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Megaripple mechanics: bimodal transport ingrained in bimodal sands
por: Tholen, Katharina, et al.
Publicado: (2022)

Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner
por: Varadarajan, Shankar, et al.
Publicado: (2015)

Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia
por: Flynn, Joseph, et al.
Publicado: (2015)

A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development
por: Healey, Gareth D., et al.
Publicado: (2019)

Bimodal Fluorescence/Magnetic Resonance Molecular Probes with Extended Spin Lifetimes
por: Yang, Shengjun, et al.
Publicado: (2022)

Low dose dinaciclib enhances doxorubicin-induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways
por: Tang, Hailong, et al.
Publicado: (2018)

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer
por: Rajput, Sandeep, et al.
Publicado: (2016)

Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma
por: Nelson, Luke J, et al.
Publicado: (2022)

Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies
por: Mita, Monica M, et al.
Publicado: (2017)

Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1‐involved pathway
por: Zhao, Huayan, et al.
Publicado: (2019)

Dinaciclib potently suppresses MCL-1 and selectively induces the cell death in human iPS cells without affecting the viability of cardiac tissue
por: Alsayegh, Khaled, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1v11ilv3q3qgm3u6fcimutmqc6